retatrutide trial phase Eli Lilly's 3 clinical studies investigating retatrutide, the "triple-G" agonist, have found that long-term use can achieve substantial weight loss. Read about the work via the link in the comments Phase III retatrutide study demonstrates

COVERAGE STRATEGY If you have prediabetes or type 2 diabetes plus obesity, push your physician to prescribe for the diabetes indication rather than weight loss

With proper monitoring and a supportive plan, it can be a powerful tool in achieving healthier, sustainable weight loss and improved overall well-being

We supply bac water for peptides strictly for research purposes

Ferrannini, E., Rosenbaum, M

Schedule a Consultation at the Center for Weight Loss Surgery It can be challenging not to gain weight after stopping Ozempic, Wegogy, Mounjaro, Zepbound and other GLP-1s, but several alternatives can be more effective in the long term

Barb Sorg for donating rapamycin